The importance of early pediatric lipid screening
Lipid screening is recommended in all children aged 9 to 11 years, regardless of health status.1 By initiating lipid screening at a young age, HCPs can proactively identify children who may be at risk from FH or other lipid disorders.1
Watch the short animated video below on the importance of early pediatric lipid screening.
Navigating pediatric lipid screening:
Considerations for communicating with patients
There can be barriers to implementing pediatric lipid screening, such as anxiety and discomfort from the patient and patients not attending their lipid screening appointments.2,3
Watch the short animated video below for information about communicating with patients about pediatric lipid screening.
Pediatric lipid screening in the US
View or download the PDF on the importance of early pediatric lipid screening. Use this to support your discussion with patients.
Pediatric lipid screening in the US
Despite guideline recommendations, pediatric lipid screening rates are low.
DownloadOvercoming barriers to implementing pediatric lipid screening:
A recent approach to pediatric lipid screening
Dr Don P. Wilson, MD, FNLA, and Dr Jason V. Terk, MD, share their experience of overcoming barriers to implementing pediatric lipid screening in clinical practice.
Hear their conversation below.
Guidelines and recommendations
Further reading for more information on pediatric lipid screening and FH diagnosis.
The National Heart, Lung and Blood Institute: Guidelines for cardiovascular health and risk reduction in children and adolescents
Guidelines recommend lipid screening for all children aged between 9 and 11 years. Screening may be performed as early as age 2 if there is a family history of high blood cholesterol levels, heart attack, or stroke.5
Visit resource
The American Heart Association: The agenda for familial hypercholesterolemia
Recommendations for heterozygous FH and homozygous FH diagnosis.6
Visit resourceThe organizations listed are independent non-profit organizations.
Their inclusion here does not imply endorsement by Regeneron nor does it imply endorsement of Regeneron or this resource center.
Discover more
Help us improve our content for you
Take this 2-minute survey to let us know what you
enjoyed about our website and what you would like to see in the future.
Your valuable input will help us tailor our content to better suit your needs.
References
-
McGowan MP et al. J Am Heart Assoc 2019;8:e013225.
-
National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK395583/ (accessed August 2023).
-
de Ferranti S et al. J Pediatr 2017;185:99–105.
-
Berger JH et al. J Am Heart Assoc 2022;11:e024197.
-
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. Pediatrics 2011;128:S213–S256.
-
Gidding SS et al. Circulation 2015;132:2167–2192.